Short Communication

Determination of asenapine in presence of its inactive metabolites in human plasma by LC-MS/MS

Nirav P. Patela,b, Mallika Sanyalb,c, Naveen Sharmaa, Dinesh S. Patela,a Pranav S. Shrivastavd,e, Bhavin N. Patela

A R T I C L E   I N F O

Article history:
Received 28 October 2017
Received in revised form
14 June 2018
Accepted 15 June 2018
Available online 18 June 2018

Keywords:
Asenapine
Asenapine 13C-d3
Metabolites
LC-MS/MS
Bioequivalence study
Human plasma

A B S T R A C T

A highly selective and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay has been described for the determination of asenapine (ASE) in presence of its inactive metabolites N-desmethyl asenapine (DMA) and asenapine-N-glucuronide (ASG). ASE, and ASE 13C-d3, used as internal standard (IS), were extracted from 300 μL human plasma by a simple and precise liquid-liquid extraction procedure using methyl tert-butyl ether. Baseline separation of ASE from its inactive metabolites was achieved on Chromolith Performance RP8e (100 mm × 4.6 mm) column using acetonitrile-5.0 mM ammonium acetate-10% formic acid (90:10:0.1, v/v/v) within 4.5 min. Quantitation of ASE was done on a triple quadrupole mass spectrometer equipped with electrospray ionization in the positive mode. The protonated precursor to product ion transitions monitored for ASE and ASE 13C-d3 were m/z 286.1 → 166.0 and m/z 290.0 → 166.1, respectively. The limit of detection (LOD) and limit of quantitation (LOQ) of the method were 0.0025 ng/mL and 0.050 ng/mL respectively in a linear concentration range of 0.050–20.0 ng/mL for ASE. The intra-batch and inter-batch precision (% CV) and mean relative recovery across quality control levels were ≤ 5.8% and 87.3%, respectively. Matrix effect, evaluated as IS-normalized matrix factor, ranged from 1.03 to 1.05. The stability of ASE under different storage conditions was ascertained in presence of the metabolites. The developed method is much simpler, matrix free, rapid and economical compared to the existing methods. The method was successfully used for a bioequivalence study of asenapine in healthy Indian subjects for the first time.

1. Introduction

Asenapine (ASE) is a second generation antipsychotic drug used for the acute treatment of manic or mixed episodes, associated with bipolar I disorder and schizophrenia [1–3]. Pharmacologically, ASE is a dibenzooxepino pyrrole drug with a tetracyclic structure. It is the ninth atypical antipsychotic agent that received regulatory approval in August 2009 from the US Food and Drug Administration (FDA) to schizophrenia and bipolar I disorder in adults [4]. It shows high affinity to serotonin receptors (5-HT1a, 5-HT1b, 5-HT2a, 5-HT2b, 5-HT2c, 5-HT5, 5-HT6, and 5-HT7), dopamine receptors (D1, D2, D3, and D4), alpha 1 and 2 receptors, histamine (H1) receptors and moderate affinity to histamine (H2) receptors. Unlike other antipsychotic agents, ASE has no appreciable affinity towards muscarinic receptors [1,4]. ASE is unique among other antipsychotics like risperidone, olanzapine and aripiprazole, in its mode of administration. It is available only as a sublingual, rapidly dissolving formulation that exposes the drug only to salivary enzymes and bypasses first pass metabolism. When administered sublingually, it has a bioavailability of about 35%, while the oral bioavailability is only 2%, when swallowed [5]. The time taken to achieve the maximum drug plasma concentration (t_{max}) after a single 5 mg dose is about 1 h. ASE is highly protein bound (95%), primarily to albumin and alpha-acid glycoprotein and shows excellent penetration across the blood–brain barrier. Asenapine is metabolized to several metabolites; however, none of them have any significant pharmacological activity. The primary mechanism of metabolism involves glucuronidation through UDP glucuronosyl transferase 1A4 (UGT1A4), producing asenapine-N-glucuronide (ASG). The other major metabolite of ASE is N-desmethyl asenapine (DMA), which is formed via demethylation, mainly through CYP1A2, with only minor contributions from CYP3A4 and CYP2D6 [2,6].

Peer review under responsibility of Xi’an Jiaotong University.
* Correspondence author.
E-mail address: pranav_shrivastav@yahoo.com (P.S. Shrivastav).

https://doi.org/10.1016/j.jpha.2018.06.002

2018 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Literature presents few methods to determine ASE in biological samples [7–11]. Van de Wetering-Krebers et al. [7] studied the excretion balance and metabolism routes of ASE in humans and determined its plasma, urine and fecal concentration using high-performance liquid chromatography (HPLC). A gas chromatography-mass spectrometry (GC-MS) method is also described to analyze ASE in postmortem samples [8]. Reddy et al. [9] have presented a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous determination of ASE and valproic acid in human plasma. Two other methods describe quantification of ASE and its inactive metabolites in human plasma [10] and urine [11] using LC-MS/MS. In these methods [10,11], two separate assays were developed, one for ASE, DMA and 11-O-sulfate asenapine (OSA) and the other for ASG, respectively under gradient elution. In the present work a highly selective and sensitive LC-MS/MS assay is developed to determine ASE in human plasma in presence of its inactive metabolites, ASG and DMA. The assay presents a straightforward liquid-liquid extraction (LLE) extraction procedure to obtain a precise and quantitative recovery of ASE. The proposed method was successfully applied to a bioequivalence study of 10 mg asenapine sublingual tablet formulation in 14 healthy subjects under fasting.

2. Experimental

2.1. Chemicals and materials

Reference standards of asenapine (ASE, 99.6%), asenapine 13C-d3 (IS, 99.5%), N-desmethyl asenapine (DMA, 99.1%) and asenapine-N-glucuronide (ASG, 98.7%) were procured from Clearsynth Labs (P) Ltd. (Mumbai, India). HPLC grade methanol and acetonitrile, analytical grade formic acid, ammonia and ammonium acetate was maintained at 4 °C until use.

2.2. LC-MS/MS instrumentation and conditions

The liquid chromatography system from Shimadzu (Kyoto, Japan) consisted of an LC-10ADvp pump, an autosampler (SIL-HTc) and an on-line degasser (DGU-14A). Chromatographic column used was Chromolith Performance RP18e (100 mm × 4.6 mm) from Merck (Mumbai, India). The mobile phase consisted of acetonitrile–5.0 mM ammonium acetate-10% formic acid in 90:10:0.1 (v/v/v) ratio, delivered at a flow rate of 0.9 mL/min. The auto sampler temperature was maintained at 4 °C and the injection volume was kept at 5.0 μL. Ionization and detection of ASE and IS was performed on a triple quadrupole mass spectrometer, API-4000 equipped with turbo ion spray from MDS SCIEX (Toronto, Canada) and was operated in the positive ionization mode. Quantitation was performed using multiple reaction monitoring (MRM) mode to monitor protonated precursor → product ion transition of m/z 286.1 → 166.0 for ASE and m/z 290.0 → 166.1 for IS. All the parameters of LC and MS were controlled by Analyst software version 1.6.2. The optimized mass parameters are summarized in Supplementary material.

2.3. Preparation of calibration and quality control samples

The calibration standards (CSs) were made at 0.05, 0.10, 0.20, 0.50, 1.00, 2.00, 4.00, 8.00, 16.0 and 20.0 ng/mL for ASE. Six quality control (QC) samples were prepared at the following concentrations, 0.05 ng/mL (LLOQ QC, lower limit of quantitation quality control), 0.15 ng/mL (LQC, low quality control), 1.50/5.00 ng/mL (MQC-1/MQC-2, medium quality control), 15.0 ng/mL (HQC, high quality control) and 20.0 ng/mL (ULOQ QC, upper limit of quantitation quality control).

2.4. Protocol for sample preparation

Prior to analysis, spiked plasma/subject samples were thawed and allowed to equilibrate at room temperature. The samples were adequately vortexed before pipetting. Aliquots of 300 μL plasma solutions containing 15 μL of working solution of ASE and 285 μL blank plasma were transferred into screw cap tubes. To which, 25 μL of methanol: deionized water (60:40, v/v), 50 μL working solution of IS (25.0 ng/mL) was added and vortexed to mix. Further, 500 μL of 5.0 mM ammonium acetate solution (pH 9, adjusted with ammonia) was added and vortexed again. LLE was carried out using 3.0 mL of MTBE by centrifuging the samples for 5.0 min at 1811 g. After freezing the aqueous layer in dry ice bath, the organic layer was transferred in clean pre-labeled glass tubes. The samples were then evaporated to dryness at 40 °C under gentle stream of nitrogen. The dried samples were reconstituted with 500 μL of mobile phase solution and 5.0 μL was used for injection in LC-MS/MS, in partial loop mode.

2.5. Methodology for validation

Method validation for ASE in human plasma was done following the USFDA guidelines [12] and the procedures followed were similar to our previous work [13]. The details are described in Supplementary material.

2.6. Bioequivalence study design and incurred sample reanalysis (ISR)

The design of study comprised an open label, randomized, two-period, two-treatment, two-sequence, crossover, balanced, single dose, evaluation of relative oral bioavailability of test (10 mg asenapine sublingual orally disintegrating tablet from an Indian company) and reference formulations (SAPHRIS®, 10 mg asenapine sublingual orally disintegrating tablet from Merck Sharp & Dohme Company, Whitehouse Station, NJ08889, USA) in 14 healthy adult Indian subjects under fasting. The procedures followed while dealing with human subjects were based on International Conference on Harmonization, E6 Good Clinical Practice guidelines [14]. An incurred sample reanalysis (ISR) was also conducted by computerized selection of 70 subject samples near Cmax and the elimination phase for the study as reported previously [15]. The experimental details for the study along with statistical analysis are described in Supplementary material.

3. Results and discussion

3.1. Method development

The objective of the present work was to develop and validate a selective and sensitive method for ASE in presence of its inactive metabolites by LC-MS/MS and to apply the method for a bioequivalence study of ASE sublingual tablet formulation in healthy subjects. Furthermore, the sensitivity of the method should be such that it can monitor at least five half lives of ASE concentration with good accuracy and precision for the analysis of subject samples. Though there are reports on the simultaneous determination of ASE and its metabolites in human plasma and urine [10,11], two different methods were adopted to determine ASG.
| Sr. No. | Linear range (ng/mL) | Sample volume | Extraction procedure | Chromatography column; elution mode and mobile phase; flow rate | Retention time; run time | Application |
|--------|----------------------|----------------|----------------------|---------------------------------------------------------------|--------------------------|-------------|
| 1      | 0.1-10.02 for ASE     | 300 µL plasma  | Liquid-liquid extraction with methyl tert-butyl ether | Chromolith RP8e (100 mm × 4.6 mm, 5 µm); isocratic elution using 10 mM ammonium formate–acetonitrile (5:95,v/v); 0.5 mL/min | 3.63 min (ASE), 3.59 min (DMA); 3.59 min (OSA); 8.0 min (ASM); 8.0 min (ASG) | Pharmacokinetic study with 5.0 mg asenapine in 8 healthy subjects |
| 2      | 0.025–20.0 for ASE    | 500 µL plasma  | Automated solid-phase extraction using Oasis HLB extraction plate | Chromolith RP8e (100 mm × 4.6 mm, 5 µm); isocratic elution using 10 mM ammonium formate–acetonitrile (5:95,v/v); 0.5 mL/min | 3.63 min (ASE), 3.59 min (DMA); 3.59 min (OSA); 8.0 min (ASM); 8.0 min (ASG) | Analysis of plasma asenapine (1.0, 3.0 or 5.0 mg) in phase I clinical trial samples from 24 healthy subjects |
| 3      | 0.50-100 for ASE, and OSA 0.15–500 for ASE | 150 µL urine and 45–500 µL human plasma | Online solid-phase extraction with a M-Balzola Oasis HLB extraction plate | Chromolith Performance RP8e (100 mm × 4.6 mm, 5 µm); isocratic elution using 10 mM ammonium formate-acetonitrile-5 mM ammonium acetate-10 % formic acid (pH 5.5) in 90:10:0.1 (v/v/v) for both the methods; 0.5 mL/min | 3.63 min (ASE), 3.59 min (DMA); 3.59 min (OSA); 8.0 min (ASM); 8.0 min (ASG) | Bioequivalence study with 5.0 mg sublingual tablet in 14 healthy subjects |
| 4      | 0.050-20 for ASE      | 300 µL human plasma | Liquid-liquid extraction with methyl tert-butyl ether in an alkaline medium | Chromolith Performance RP8e (100 mm × 4.6 mm, 5 µm); isocratic elution using 10 mM ammonium formate-acetonitrile-5 mM ammonium acetate-10 % formic acid (pH 5.5) in 90:10:0.1 (v/v/v) for both the methods; 0.5 mL/min | 3.63 min (ASE), 3.59 min (DMA); 3.59 min (OSA); 8.0 min (ASM); 8.0 min (ASG) | Bioequivalence study with 10.0 mg sublingual tablet in 14 healthy subjects |

**Notes:**
- Together with valproic acid.
- Along with N-desmethyl asenapine (DMA), 11-α-sulfate asenapine (OSA), and asenapine N-glucuronide (ASG).
- Along with DMA and ASG.
- PM: Present method.
elution, which is not possible with the existing LC-MS/MS methods employing gradient elution program [10,11]. Further, it was not feasible to analyze ASG along with ASE and other metabolites due to difference in polarity and therefore a separate method was established for ASG [10]. Besides, the newly developed method presents an efficient, relatively inexpensive and straightforward extraction procedure for precise and quantitative recovery of ASE in presence of its inactive metabolites. Though the sensitivity of ASE achieved (0.05 ng/mL) was less than the work of de Boer et al. [10] (0.025 ng/mL), it was higher than that of another report (0.10 ng/mL) [9]. On the other hand, the analysis time of 4.5 min was shorter than in methods reported for the determination of ASE together with its metabolites [10,11]. The plasma volume used for processing is less (300 µL) compared to the work of de Boer et al. [10], which employed 500 µL sample volume. Moreover, their method involved an automated SPE using 96-well plate which is not used routinely. A comparative evaluation of methods developed for ASE is illustrated in Table 1.

3.2. Assay performance and validation

The selectivity of the method from endogenous plasma components was determined by analyzing eight different human plasma sources. This was done to evaluate the extent to which matrix
components may interfere at the retention time of ASE and the IS. Fig. 1 demonstrates the selectivity of the method with the chromatograms of double blank plasma, blank plasma spiked with IS, ASE at LLOQ and ULOQ concentration and in subject samples. Carry-over evaluation was performed in each analytical run to ensure that it does not impact the accuracy and precision of the method. The results showed a carryover of $r^2 = 0.23\%$ for ASE concentration (0.05 ng/mL) in the blank plasma sample after injection of highest calibration standard (ULOQ) at the retention time of ASE. Further, there was no interference of commonly used medications by healthy volunteers like acetaminophen, aspirin, caffeine, chlorpheniramine, cetirizine, ibuprofen and pseudoephedrine at the retention time of ASE and IS. Similarly, none of the metabolites (DMA and ASG) interfered in the determination of ASE as they were chromatographically separated.

The calibration curve was linear over the concentration range of 0.05–20.0 ng/mL with correlation coefficient $r^2 = 0.9996$. A | Inter-day ($n = 18$; 6 from each batch) |
|-----------------|-----------------|-----------------|
| Mean conc. found (ng/mL) | Accuracy (%) | CV (%) |
| LLOQ (0.050) | 0.046 | 91.4 | 5.8 |
| LQC (0.150) | 0.140 | 93.0 | 4.0 |
| MQC-1 (1.500) | 1.455 | 97.0 | 2.4 |
| MQC-2 (5.000) | 4.653 | 93.1 | 2.8 |
| HQC (15.00) | 13.68 | 91.2 | 3.0 |
| ULOQ (20.00) | 18.37 | 91.9 | 3.4 |

LLOQ QC: lower limit of quantitation quality control; LQC: low quality control; MQC: medium quality control; HQC: high quality control; CV: coefficient of variation.

Table 3
Extraction recovery and matrix factor for asenapine in presence of its metabolites ($n = 6$).

| Quality control level (ng/mL) | Mean area response ($n = 6$) | Recovery (B/A %) | Matrix factor |
|------------------------------|--------------------------------|-----------------|--------------|
|                               | A (post-extraction spiking)   | B (pre-extraction spiking) | C (neat samples in mobile phase) | Analyte IS | Analyte (A/C) IS | IS-normalized (analyte/IS) |
| 0.150                         | 17,557                        | 14,961           | 17,734       | 85.2 | 86.3 | 0.99 | 0.94 | 1.05 |
| 1.500                         | 173,238                       | 154,888          | 176,773      | 89.4 | 87.3 | 0.98 | 0.95 | 1.03 |
| 5.000                         | 551,223                       | 480,015          | 568,271      | 87.1 | 86.8 | 0.97 | 0.93 | 1.04 |
| 15.00                         | 1,598,648                     | 1,398,270        | 1,614,796    | 87.5 | 88.0 | 0.99 | 0.96 | 1.03 |

IS: internal standard, asenapine 13C-d3.

Table 4
Stability results for asenapine under different conditions ($n = 6$).

| Storage condition                  | Quality control level (ng/mL) | In absence of metabolites | In presence of metabolites (20.0 ng/mL of DMA and ASG) |
|------------------------------------|-------------------------------|--------------------------|--------------------------------------------------------|
|                                   | Mean stability sample (ng/mL) | CV (%) | Change (%) | Mean stability sample (ng/mL) | CV (%) | Change (%) |
| Bench top stability (24 h, 25 °C)  | 0.150                         | 0.138 | 2.4 | – 8.0 | 0.155 | 2.3 | 3.3 |
|                                    | 15.00                         | 0.138 | 2.4 | – 8.0 | 0.144 | 2.3 | 3.7 |
| Freeze-thaw stability (6 cycles, −20 °C) | 0.150               | 0.140 | 2.8 | – 6.9 | 0.154 | 3.0 | 3.1 |
|                                    | 15.00                         | 0.141 | 4.6 | – 6.1 | 0.143 | 4.3 | 2.3 |
| Auto sampler stability (94 h, 5 °C) | 0.150                         | 0.138 | 2.6 | – 8.0 | 0.139 | 3.2 | 4.1 |
|                                    | 15.00                         | 0.138 | 2.6 | – 8.0 | 13.94 | 4.7 | 5.3 |
| Processed sample stability (75 h, 25 °C) | 0.150               | 0.138 | 2.6 | – 8.0 | 0.139 | 3.2 | 4.1 |
|                                    | 15.00                         | 0.138 | 2.6 | – 8.0 | 13.94 | 4.7 | 5.3 |
| Long-term stability (126 days, −20 °C) | 0.150                         | 0.139 | 2.9 | – 7.7 | – | – | – |
|                                    | 15.00                         | 0.137 | 4.7 | – 8.4 | – | – | – |
| Long-term stability (126 days, −70 °C) | 0.150                         | 0.137 | 4.7 | – 8.4 | – | – | – |
|                                    | 15.00                         | 0.142 | 3.9 | – 5.0 | – | – | – |

CV: coefficient of variation; DMA: N-desmethyl asenapine; ASG: asenapine N-glucuronide.

Change (%) = \( \frac{\text{Mean stability samples} - \text{Mean comparison samples}}{\text{Mean comparison samples}} \times 100. \)

Fig. 2. Mean plasma concentration-time profile of asenapine after sublingual administration of 10 mg tablet (test and reference) formulation to 14 healthy Indian subjects under fasting.
straight-line fit was made through the data points by least square regression analysis to give a mean linear equation, $y = (1.2033 \pm 0.0035)x - (0.0091 \pm 0.0007)$, where $y$ is the peak area ratio (ASE/IS) and $x$ is the concentration of ASE. The accuracy and precision ($\% CV$) observed for the CSs ranged from 97.3% to 102.3% and 0.6%–2.3%, respectively. The lowest concentration (ULOQ) that was measured with acceptable accuracy and precision was 0.05 ng/mL at $S/N \geq 15$, and the limit of detection (LOD) of the method was 0.0025 ng/mL.

The intra-batch and inter-batch precision and accuracy results are summarized in Table 2. The intra-batch precision ($\% CV$) ranged from 1.3% to 2.8% and the accuracy was within 94.1%–99.5%. For the inter-batch experiments, the precision varied from 2.4% to 5.8% and the accuracy was within 91.2%–97.0%. The extraction recovery and matrix effect data for ASE and IS are shown in Table 3. Highly consistent recovery was obtained across QC levels for ASE and its IS. Post-column infusion further substantiated the absence of matrix effects with no signal enhancement or suppression at the retention time of ASE or ASE 13C-d3.

Table 5 gives the values of pharmacokinetic parameters of test and reference formulations and equivalence statistics of bioavailability for the pharmacokinetic parameters. The results obtained for $C_{max}$, $T_{max}$, $t_{1/2}$ and AUC were in good agreement with reported studies [3,5,9]. Further, the 90% confidence intervals of the test/reference formulations for $C_{max}$, $AUC_{0-t}$, and $AUC_{0-inf}$ varied from 83.4% to 97.3%, which is within the bioequivalence acceptance criterion of 80%–125%. No statistically significant differences were found between the two formulations in any parameter. Further, there was no adverse event during the course of the study. The % change in the measurement of selected subject samples for ISR was within ± 14.5%, which confirms method reproducibility.

### 4. Conclusion

In summary, we have described a selective and sensitive LC-MS/MS method for the estimation of ASE in human plasma, especially to meet the requirement for subject sample analysis. The inactive metabolites, DMA and ASG, were successfully resolved on a monolithic silica column. The LLE procedure employed in the present work gave consistent and reproducible recovery for ASE. The optimized linear concentration range was adequate to monitor at least five half-lives of ASE with good accuracy and precision. Furthermore, the results of the reassay of study data have shown sufficient reproducibility of the method.

### Conflicts of interest

The authors declare that there are no conflicts of interest.

### Acknowledgments

The authors are indebted to Mr. Vijay Patel, Executive Director, Cliantha Research Ltd., Ahmedabad, India, for providing necessary facilities to carry out this work and to Mr. Anshul Dogra, Head of the Department, Cliantha Research Ltd., for his support during the course of this project.
Appendix A. Supplementary material

Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.jpha.2018.06.002.

References

[1] T. Scheidemantel, I. Korobkova, S. Rej, et al., Asenapine for bipolar disorder, Neuropsychiatr. Dis. Treat. 11 (2015) 3007–3017.
[2] J.M. Gonzalez, P.M. Thompson, T.A. Moore, Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder, Patient Prefer. Adherence 5 (2011) 333–341.
[3] Saphris® (asenapine) sublingual tablets. Full prescribing information, Schering Corporation, a subsidiary of Merck & Co. Inc., Whitehouse Station, NJ. [https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022117s017s018s019lbl.pdf]. (Assessed September 2017).
[4] C.G. Warren, S.L. Dubovsky, New approaches for the management of bipolar disorder: role of sublingual asenapine in the treatment of mania, Neuropsychiatr. Dis. Treat. 9 (2013) 753–758.
[5] L. Citrome, Role of sublingual asenapine in treatment of schizophrenia, Neuropsychiatr. Dis. Treat. 7 (2011) 325–339.
[6] M. Pompili, P. Venturini, M. Innamorati, et al., The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder, Neuropsychiatr. Dis. Treat. 7 (2011) 259–265.
[7] S.F.M. van de Wetering-Krebbers, P.L. Jacobs, G.J. Kemperman, et al., Metabolism and excretion of asenapine in healthy male subjects, Drug Metab. Dispos. 39 (2011) 580–590.
[8] C. Miller, O. Pleitez, D. Anderson, et al., Asenapine (Saphris®): gc-ms method validation and the postmortem distribution of a new atypical antipsychotic medication, J. Anal. Toxicol. 37 (2013) 559–564.
[9] A.V.B. Reddy, N. Venugopal, G. Madhavi, Simultaneous determination of asenapine and valproic acid in human plasma using LC-MS/MS: application of the method to support pharmacokinetic study, J. Pharm. Anal. 3 (2013) 394–401.
[10] T. de Boer, E. Meulman, H. Meijering, et al., Quantification of asenapine and three metabolites in human plasma using liquid chromatography-tandem mass spectrometry with automated solid-phase extraction: application to a phase I clinical trial with asenapine in healthy male subjects, Biomed. Chromatogr. 26 (2012) 156–165.
[11] T. de Boer, E. Meulman, H. Meijering, et al., Development and validation of automated SPE-HPLC-MS/MS method for the quantification of asenapine, a new antipsychotic agent, and its two major metabolites in human urine, Biomed. Chromatogr. 26 (2012) 1481–1483.
[12] Guidance for industry, bioanalytical method validation, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM), May 2001.
[13] N.P. Patel, M. Sanyal, N. Sharma, et al., Highly sensitive LC-MS/MS method to estimate doxepin and its metabolite nordoxepin in human plasma for a bioequivalence study, J. Pharm. Anal. [http://dx.doi.org/10.1016/j.jpha.2017.06.004].
[14] Guidance for Industry: ICH E6 good clinical practice, U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Centre for Biologics Evaluation and Research (CBER), 1996.
[15] M. Yadav, P.S. Shrivastav, Incurred sample reanalysis: a decisive tool in bioanalytical research, Bioanalysis 3 (2011) 1097–1104.
[16] SAPHRIS® (asenapine maleate), Product information, Merck Sharp & Dohme Pty Limited 54-68 Ferndell Street, South Granville, NSW 2142, Australia. [https://gg2u.com.au/static/pdf/SAPHRIS-PI.pdf]. (Assessed September 2017).